An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 26 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.
- 04 Jun 2018 New trial record